SGHT trades 4.2% below Wall Street's consensus target of $10.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes SGHT achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Sight Sciences, Inc. (SGHT) has a Wall Street consensus price target of $10.50, based on estimates from 9 covering analysts. With the stock currently trading at $10.08, this represents a potential upside of +4.2%. The company has a market capitalization of $548M.
Analyst price targets range from a low of $7.00 to a high of $14.00, representing a 67% spread in expectations. The median target of $10.50 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 1 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, SGHT trades at a trailing P/E of -19.6x. Analysts expect EPS to grow +1.3% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 GKOSGlaukos Corporation | $13.2B | $224.41 | $218.70 | -2.5% | Buy | 332.7x | 25 |
 ATRCAtriCure, Inc. | $3.0B | $58.54 | $60.17 | +2.8% | Buy | 541.5x | 20 |
 NVCRNovocure Ltd | $1.5B | $13.28 | $26.00 | +95.8% | Buy | — | 15 |
 TNDMTandem Diabetes Care, Inc. | $1.2B | $16.91 | $23.19 | +37.1% | Buy | — | 39 |
 ABTAbbott Laboratories | $191.5B | $109.93 | $121.36 | +10.4% | Buy | 19.9x | 43 |
 MDTMedtronic plc | $130.7B | $101.80 | $97.73 | -4.0% | Buy | 17.0x | 51 |
 SYKStryker Corporation | $124.9B | $325.87 | $354.47 | +8.8% | Buy | 22.0x | 52 |
 BSXBoston Scientific Corporation | $63.5B | $42.75 | $54.65 | +27.8% | Buy | 13.5x | 44 |
 ALGNAlign Technology, Inc. | $11.9B | $166.00 | $190.00 | +14.5% | Buy | 14.9x | 33 |
 RXSTRxSight, Inc. | $188M | $4.54 | $7.05 | +55.3% | Hold | — | 12 |
Quick answers to the most common questions about buying SGHT stock.
The consensus price target for SGHT is $10.5, close to the current price of $10.08 (4.2% implied move). Based on 9 analyst estimates, the stock appears fairly valued near current levels.
SGHT has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is mixed, with 4 Hold ratings making up the largest segment. The consensus 12-month price target of $10.5 implies 4.2% upside from current levels.
SGHT's current price is $10.08 with a consensus target of $10.5 (4.2% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $14 for SGHT, while the most conservative target is $7. The consensus of $10.5 represents the median expectation. These targets typically reflect 12-month expectations.
SGHT is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 4 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month SGHT stock forecast based on 9 Wall Street analysts shows a consensus price target of $10.5, with estimates ranging from $7 (bear case) to $14 (bull case). The median consensus rating is "Buy".
SGHT appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $10.5 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
SGHT analyst price targets range from $7 to $14, a 67% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $10.5 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.